Services
TissUse offers high-value service contracts to create custom solutions for safety evaluation of drugs, cosmetics and chemicals, and pre-clinical human disease modelling. Any new chip design serving customer needs with a specific organ arrangement can be prototyped and produced at short notice due to a proprietary rapid prototyping procedure established at TissUse.
The versatile TissUse approach addresses multiple organs & tissues to make the right chip for the right assay.
![TissUse Multi organ Chip assay TissUse Multi organ Chip assay](files/upload/technology/tissuse-multi-organ-chip-assay.jpg)
Drug development
![](assets/images/d/210426_phasen_medikamentenentwicklung2_fast_forward-999ee071.png)
Our goal is to deliver the tools to accelerate drug development through these stages together with all the scientists over the world towards patient’s benefit. Our experienced team with long-standing expertise in Multi-Organ-Chip assay development (>50 MOC publications) will design your flexible, efficient and reliable assay for safety or efficacy testing.
- Safety: Identify hazards before moving on to exposing organisms with your substance of interest.
- Efficacy: Get early and strong indication of your substance performance early in the development process.
Our HUMIMIC assay pipeline
DMPK / Safety / Hazard identification
Mode of Action / Efficacy
No. | Organ model | Schematic | Context of use | Level of readiness | Species |
1 | Blood-Brain-barrier – Neuro – Liver | ![]() |
BBB permeability, organ toxicity, metabolite neurotoxicity | III | Human |
2 | Bone marrow | ![]() |
Bone marrow toxicity, chemotherapy scheduling, erythropoiesis | III | Human |
3 | Hair follicle | ![]() |
Hair growth agents | III | Human |
4 | Intestine – Liver | ![]() |
Absorption, metabolism | III | Human |
5 | Intestine – Liver – Kidney – Neuro | ![]() |
ADME-profiling, PBPK, first-path metabolism, primary & secondary organ toxicity | III | Human |
6 | Intestine – Liver – Kidney – Neuro + Blood-Brain-Barrier | ![]() |
ADME-profiling, PBPK, first-path metabolism, primary & secondary organ toxicity | III | Human |
7 | Lung – Liver | ![]() |
Hazard identification | III | Human |
8 | Pancreas – Liver | ![]() |
Diabetes target finding, mathematical modeling | III | Human |
9 | Skin – Liver | ![]() |
Compound PK/PD, skin irritancy, toxicity, first-path metabolism | III | Human |
10 | Skin – Tumor | ![]() |
Anti-tumor antibodies | III | Human |
11 | Thyroid – Liver | ![]() |
Endocrine disruption | III | Human vs. Rat |
12 | Liver | ![]() |
Drug evaluation | II | Human |
13 | Lung | ![]() |
Nanoparticle toxicity | II | Human |
14 | Skin – Liver – Thyroid | ![]() |
Repeated dose topical and systemic administration | II | Human |
15 | Testis – Liver | ![]() |
Testicular toxicity | II | Human |
16 | Vasculature – Pancreas – Tumor | ![]() |
Anti-tumor therapy | II | Human |
17 | Bone | ![]() |
Nanoparticle toxicity | I | Human |
18 | Cardio – Liver | ![]() |
Metabolite cardiotoxicity | I | Human |
19 | Endometrium | ![]() |
Physiology/Pathology | I | Human |
20 | Intestine – Skeletal muscle | ![]() |
Muscle growth agents | I | Human vs. Pig |
21 | Kidney (glomerulus) – Liver | ![]() |
Therapeutic effect of MSC-derived extracellular vesicles | I | Human |
22 | Kidney (proximal tubules) – Liver | ![]() |
Repeated dose proximal tubules toxicity | I | Human |
23 | Neuro – Liver | ![]() |
Metabolite neurotoxicity | I | Human |
24 | Immunocompetent Skin – Gingiva | ![]() |
Skin and oral toxicity | I | Human |
25 | Skin including dermal papillae | ![]() |
Skin sensitizer | I* | Human |
26 | Skin – Leukocytes | ![]() |
Allograft rejection therapies | I | Human |
27 | Tumor (DLBCL) – Liver | ![]() |
Personalized automatized cancer treatment | I | Human |
III Internally & externally qualified assay
II Internally qualified assay
I Internally/externally established biological model (Proof of concept)